Azimilide Shield 2 Study

Azimilide Shield 2 Study

Share this:

Forest Research Institute AZM-MD-302 Azimilide Shield 2


This is an event-driven randomized, multi-center, double-blind, placebo-controlled, parallel-group study of the safety and efficacy of a once-daily oral dose of 75 mg azimilide on the incidence of cardiovascular hospitalizations, cardiovascular emergency department visits, or cardiovascular deaths in patients with a transvenous ICD who have had a life-threatening ventricular arrhythmia. Patients are to be randomly assigned in a 1:1 ratio to receive daily oral doses of placebo or 75 mg of azimilide.


Inclusion Criteria:

  • At least 18 years of age with a left ventricular ejection fraction less than /=40% and have an implanted ICD

Primary Investigator(s):
William Welch, M.D.

Contact Information
Karen D. Buchanan, RN, BSN
Clinical Research Nurse
Phone: 540-981-7493